NTRB Key Statistics, Chart & Performance
The current stock price of NTRB is 4.54 USD. In the past month the price decreased by -5.26%. In the past year, price decreased by -7.69%.
NTRB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| CORT | CORCEPT THERAPEUTICS INC | 39.55 | 3.66B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B |
Related stock screener links
About NTRB
Company Profile
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Company Info
NUTRIBAND INC
121 S Orange Ave Ste 1500
Orlando FLORIDA US
CEO: Gareth Sheridan
Employees: 13
Phone: 14073776695
NUTRIBAND INC / NTRB FAQ
Can you describe the business of NUTRIBAND INC?
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
What is the stock price of NUTRIBAND INC today?
The current stock price of NTRB is 4.54 USD. The price decreased by -2.99% in the last trading session.
What is the dividend status of NUTRIBAND INC?
NTRB does not pay a dividend.
How is the ChartMill rating for NUTRIBAND INC?
NTRB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is NUTRIBAND INC (NTRB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NTRB.
Can you provide the number of employees for NUTRIBAND INC?
NUTRIBAND INC (NTRB) currently has 13 employees.
When does NUTRIBAND INC (NTRB) report earnings?
NUTRIBAND INC (NTRB) will report earnings on 2026-04-27, after the market close.
NTRB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NTRB. When comparing the yearly performance of all stocks, NTRB is a bad performer in the overall market: 84.38% of all stocks are doing better.
NTRB Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NTRB. The financial health of NTRB is average, but there are quite some concerns on its profitability.
NTRB Financial Highlights
Over the last trailing twelve months NTRB reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS decreased by -331.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -410.87% | ||
| ROE | -458.24% | ||
| Debt/Equity | 0.01 |
NTRB Forecast & Estimates
7 analysts have analysed NTRB and the average price target is 15.3 USD. This implies a price increase of 237% is expected in the next year compared to the current price of 4.54.
For the next year, analysts expect an EPS growth of -933.33% and a revenue growth 23.72% for NTRB